Zdrowie i gospodarka · 23/11/1999

FDA Releases Revised Guidance on Blood-Borne Creutzfeldt-Jakob Disease Risk

The FDA has released a revised guidance document to reduce the risk of Creutzfeldt-Jakob Disease (CJD) and New Variant Creutzfeldt-Jakob Disease (nvCJD) transmission through blood and blood products. The new guidance replaces the August 1999 document and provides updated recommendations to blood and plasma establishments and plasma derivative manufacturers.